当EGFR满足MET时:双重封锁作为下一个TKI后的标准?
Zhaohui Liao Arter1, Ross A Soo2
1Department of Medicine, School of Medicine, University of California, Irvine, Orange, CA 92868, USA.
SACHI试验显示,萨沃利提尼布加奥西默提尼布在非小细胞肺癌患者的无进展生存率几乎翻了一番. 在初始治疗失败后,这种组合为EGFR突变的MET放大肺癌患者提供了新的希望.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
- 临床试验 临床试验
背景情况:
- 具有EGFR突变和MET放大的非小细胞肺癌 (NSCLC) 在EGFR氨酸激酶抑制剂 (TKI) 失效后提出了治疗挑战.
- 目前对这一患者亚组的治疗选择有限,这凸显了对新型治疗策略的需求.
研究的目的:
- 为了评估与EGFR突变,MET增强NSCLC患者在先前EGFR TKI治疗后的化学疗法相比,SAVOLITINIB与OSIMERTINIB联合治疗的疗效.
- 在这个特定的NSCLC群体中建立EGFR和MET双重抑制的第一个第三阶段证据.
主要方法:
- SACHI试验是一项第3期研究,比较了savolitinib加 osimertinib与化疗.
- 无进展生存 (PFS) 是主要终点,次要终点包括整体生存率和客观反应率.
主要成果:
- 萨沃利提尼布加上奥西默提尼布显示PFS的显著改善,与化疗相比几乎翻了一番 (9.8个月与5.4个月).
- 疾病进展的危险比为0.34,表明组合治疗大大降低了疾病进展的风险.
结论:
- 用savolitinib和osimertinib对EGFR和MET的双抑制是一种非常有效的策略,用于EGFR突变,MET增强NSCLC患者在EGFRTKI失败后.
- 这代表了针对NSCLC的向治疗的重大进步,为难以治疗的患者群体提供了新的治疗范式.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
相关概念视频
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Receptor Tyrosine Kinases
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
